WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 06:03 UTC
-
New drug candidate BR101801 tested in patients with advanced blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 05:59 UTC
-
New hope for lymphoma patients who can't handle standard drugs
Disease control CompletedThis study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma who had severe side effects from similar drugs (ibrutinib or acalabrutinib). The goal was to see if zanubrutinib caused fewer or milder side effects while still controlling the cancer.…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
CAR-T therapy shows promise in Long-Term Follow-Up for blood cancers
Disease control CompletedThis study followed 16 patients with various B-cell cancers (like lymphoma and leukemia) who had already received CLBR001 CAR-T cells. The goal was to check for long-term side effects and see how well the treatment controlled the disease over time. Researchers monitored new or la…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for rare blood cancer: lenalidomide dose study completed
Disease control CompletedThis study looked at the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or stopped responding to other treatments. The main goal was to find a dose that is safe and tolerable. Researchers measured side effects and how many…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Experimental drug shows promise for rare blood cancer
Disease control CompletedThis study tested the drug carfilzomib in 7 people with Waldenström's macroglobulinemia, a rare blood cancer, that had returned after previous treatment. The goal was to see if the drug could shrink or control the cancer and to check for side effects. Carfilzomib works by blockin…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Blood and urine tests may one day replace painful bone marrow biopsies for Waldenström's patients
Knowledge-focused CompletedThis study looked at whether genetic mutations linked to Waldenström's macroglobulinemia can be detected in blood or urine samples instead of bone marrow biopsies. Researchers enrolled 300 patients to compare results from these less invasive tests with the standard bone marrow me…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 26, 2026 05:47 UTC
-
Vaccine check: how well do COVID shots protect blood cancer patients?
Knowledge-focused CompletedThis study looked at whether the COVID-19 vaccine triggers a strong immune response in people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose in 146 participants. The goal was to understand vaccin…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated May 18, 2026 11:59 UTC